Predictors of germline DNA damage repair gene mutations (gDDRm) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC).
Steven Yip(University of Calgary), Kim N.(Asian Institute of Technology), Katherine Sunderland(BC Cancer Agency), Arshia Beigi(BC Cancer Agency), Sophie Sun(Tris Pharma (United States)), Daniel Khalaf(BC Cancer Agency), Matti Annala(Tampere University), Alexander W. Wyatt(University of British Columbia), Gillian Vandekerkhove(University of British Columbia), Evan W. Warner(Guardant (United States)), Arkhjamil Angeles
Cited by 1
Related Papers
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
The evolutionary history of lethal metastatic prostate cancer
|Nature|2015|1.4k
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2012|1.4k